Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The National Institute of Allergy and Infectious Diseases (NIAID) has awarded an advanced technology Phase II small business innovation research (SBIR) grant of $3m to G-Zero Therapeutics.
Subscribe to our email newsletter
G-Zero will use the award to continue studies towards ‘Organismal Radioprotection through Pharmacological Quiescence’.
Previously in late 2009, the company has also received $0.6m through a phase I grant.
G-Zero Therapeutics CSO Jay Strum said this funding will continue to allow G-Zero’s scientists to progress lead candidates through IND-enabling studies.
"We are encouraged by NIAID’s recognition of CDK4/6 inhibitors as radiomitigants, and we are excited to receive this award," Strum said.
G-Zero is focused on the discovery and development of small molecule inhibitors to provide protection of bone marrow and other organs including the kidney and lung from radiation exposure.